Expert consensus on the treatment of tuberculosis with contezolid

doi:10.19982/j.issn.1000-6621.20240480

Abstract

Abstract:

Contezolid, a novel generation of oxazolidinone antibiotics independently developed in China, has been approved for the treatment of complex skin and soft tissue infections. With its expanding exploratory applications in the clinical management of tuberculosis and the ongoing growth of related clinical research, there is an increasing demand among clinicians for comprehensive guidelines and standardized protocols for its use. To address this need, the Editorial Board of the Chinese Journal of Antituberculosis and the Chinese Antituberculosis Association convened experts nationwide for in-depth discussions, culminating in the development of the Expert consensus on the treatment of tuberculosis with contezolid. This consensus aims to standardize and guide healthcare professionals in the use of contezolid for tuberculosis treatment, addressing uncertainties arising from the lack of specified indications, dosages, or treatment durations in current drug labels and existing antituberculosis guidelines. It is hoped that this consensus will serve as a valuable reference for practitioners in China and contribute to the rational and effective application of contezolid in clinical practice.

Key words: Oxazolidinones, Contezolid, Antitubercular agents, Therapeutic applications, Consensus guidelines

CLC Number:

Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Inspire-CODA Research Group. Expert consensus on the treatment of tuberculosis with contezolid[J]. Chinese Journal of Antituberculosis, 2025, 47(2): 123-129. doi: 10.19982/j.issn.1000-6621.20240480

Figures/Tables 1

References 31

[1]	World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
[2]	中华医学会结核病学分会. 抗结核药物超说明书用法专家共识(2023年更新版). 中华结核和呼吸杂志, 2023, 46(11): 1085-1102. doi:10.3760/cma.j.cn112147-20230809-00062.
[3]	首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 中国防痨协会,《中国防痨杂志》编辑委员会. 耐药肺结核全口服化学治疗方案中国专家共识(2021年版). 中国防痨杂志, 2021, 43(9): 859-866. doi:10.3969/j.issn.1000-6621.2021.09.002.
[4]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization, 2022.
[5]	Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020, 382(10): 893-902. doi:10.1056/NEJMoa1901814.
[6]	Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med, 2020, 8(4): 383-394. doi:10.1016/S2213-2600(20)30047-3. pmid: 32192585
[7]	康替唑胺片(优喜泰^®)说明书. 2023年版. 浙江华海药业股份有限公司.
[8]	Gordeev MF, Yuan ZY. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem, 2014, 57(11): 4487-4497. doi:10.1021/jm401931e. pmid: 24694071
[9]	Song T, Lee M, Jeon HS, et al. Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resis-tant Tuberculosis. EBioMedicine, 2015, 2(11): 1627-1633. doi:10.1016/j.ebiom.2015.09.051.
[10]	Wright A, Deane-Alder K, Marschall E, et al. Characterization of the Core Ribosomal Binding Region for the Oxazolidone Family of Antibiotics Using Cryo-EM. ACS Pharmacol Transl Sci, 2020, 3(3): 425-432. doi:10.1021/acsptsci.0c00041. pmid: 32566908
[11]	An H, Sun W, Liu X, et al. In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosis. Microbiol Spectr, 2023, 11(5): e0462722. doi:10.1128/spectrum.04627-22.
[12]	Wang C, Wang G, Huo F, et al. Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China. Front Med (Lausanne), 2022, 9: 1067516. doi:10.3389/fmed.2022.1067516.
[13]	Shoen C, DeStefano M, Hafkin B, et al. In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2018, 62(8): e00493-18. doi:10.1128/AAC.00493-18.
[14]	Almeida D, Li SY, Lee J, et al. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis. Antimicrob Agents Chemother, 2023, 67(12): e0078923. doi:10.1128/aac.00789-23.
[15]	袁红, 王星海, 张菁. 唑烷酮类抗耐药菌新药——康替唑胺. 中国感染与化疗杂志, 2021, 21(6): 765-772. doi:10.16718/j.1009-7708.2021.06.027.
[16]	Jiang G, Liu R, Ge Q, et al. Contezolid demonstrated equivalent efficacy to linezolid in tuberculosis treatment in an early bactericidal activity study//ESCMID Global. ESCMID Global, 2024: 625.
[17]	Wang J, Nie W, Ma L, et al. Clinical Utility of Contezolid-Containing Regimens in 25 Cases of Linezolid-Intolerable Tuberculosis Patients. Infect Drug Resist, 2023, 16: 6237-6245. doi:10.2147/IDR.S425743. pmid: 37745897
[18]	聂文娟, 孙峰, 王雪钰, 等. 含新药口服短程方案治疗利福平耐药肺结核患者的多中心随机对照临床试验. 中国防痨杂志, 2024, 46(11): 1313-1319. doi:10.19982/j.issn.1000-6621.20240281.
[19]	燕娜, 王庆枫, 王隽, 等. 包含康替唑胺的全新口服化学治疗方案治疗准广泛耐药肺结核1例. 中华传染病杂志, 2023, 41(8): 529-531. doi:10.3760/cma.j.cn311365-20230301-00059.
[20]	中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10): 1025-1073. doi:10.3969/j.issn.1000-6621.2019.10.001.
[21]	Wang J, Ma L. Tuberculosis patients with special clinical conditions treated with contezolid: three case reports and a literature review. Front Med (Lausanne), 2023, 10: 1265923. doi:10.3389/fmed.2023.1265923.
[22]	Li J, Yu Z, Jiang Y, et al. Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid-a typical case report and literature review. Front Cell Infect Microbiol, 2023, 13: 1258561. doi:10.3389/fcimb.2023.1258561.
[23]	Fu W, Deng ZW, Wang P, et al. A complex case study: coexistence of multi-drug-resistant pulmonary tuberculosis, HBV-related liver failure, and disseminated cryptococcal infection in an AIDS patient. BMC Infect Dis, 2024, 24(1): 533. doi:10.1186/s12879-024-09431-9.
[24]	Guo W, Hu M, Xu N, et al. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: A case report. Int J Antimicrob Agents, 2023, 62(2): 106875. doi:10.1016/j.ijantimicag.2023.106875.
[25]	Xu Z, Zhang J, Guan T, et al. Case report: Successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid. Front Med (Lausanne), 2023, 10: 1224179. doi:10.3389/fmed.2023.1224179.
[26]	Kang Y, Ge C, Zhang H, et al. Compassionate Use of Conte-zolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker. Infect Drug Resist, 2022, 15: 4467-4470. doi:10.2147/IDR.S373082.
[27]	Liu W, Yang L, Qin H, et al. Successful Treatment of Intractable Tuberculous Peritonitis in a Woman with Chronic Kidney Allograft Dysfunction Using Contezolid Containing Regimen. Infect Drug Resist, 2024, 17: 2713-2718. doi:10.2147/IDR.S465350. pmid: 38974317
[28]	中华医学会结核病学分会, 利奈唑胺抗结核治疗专家共识编写组. 利奈唑胺抗结核治疗专家共识. 中华结核和呼吸杂志, 2018, 41(1): 14-19. doi:10.3760/cma.j.issn.1001-0939.2018.01.006.
[29]	中华医学会结核病学分会. 利奈唑胺抗结核治疗专家共识(2022年版). 中华结核和呼吸杂志, 2022, 45(10): 988-995. doi:10.3760/cma.j.cn112147-20220320-00220.
[30]	那鹏, 刘婷婷, 袁亚平, 等. 康替唑胺与利奈唑胺对70岁以上重症院内获得性肺炎患者的疗效比较. 解放军医学院学报, 2024, 45(3): 239-244,251. doi:10.12435/j.issn.2095-5227.2024.001.
[31]	Shi S, Feng B, Li D, et al. Treatment of Tuberculous Pleurisy With Contezolid in a Child With Glucose-6-phosphate Dehydrogenase Deficiency: The First Case Report. Pediatr Infect Dis J, 2024, 43(9): 869-871. doi:10.1097/INF.0000000000004369. pmid: 39163300

不良反应	利奈唑胺	康替唑胺^[7]
血液系统	应用利奈唑胺患者中出现骨髓抑制的报道,包括贫血、白细胞减少和血小板减少	少见引起骨髓抑制相关的血液系统参数的显著变化
	应用利奈唑胺患者至少每月进行全血细胞计数检查
	对发生重度骨髓抑制患者应考虑停用利奈唑胺治疗
神经系统	有周围神经病、视神经病变和视神经炎报道,多为治疗时间较长患者	少见与治疗相关的周围神经和视神经病变
	对长期应用利奈唑胺患者,应定期进行视觉功能问诊和监测,以及周围神经问诊和检测
其他	常见不良事件为恶心呕吐、腹痛腹泻,部分患者服药后有舌苔变黑	胃肠道反应大部分为轻度至中度,且大多呈一过性